Search

Your search keyword '"Polisetty, Radhika S"' showing total 19 results
Start Over Author "Polisetty, Radhika S"
19 results on '"Polisetty, Radhika S"'

3. 1275. Impact of a bundled antimicrobial stewardship intervention leveraging frontline pharmacist response to rapid blood culture diagnostics at an academic medical center and community hospital

Author

Bajer, Kevin, primary, Bertram, Christie M, additional, Weslander, Erin, additional, Qi, Chao, additional, Moore, William J, additional, Polisetty, Radhika S, additional, Postelnick, Mike, additional, Zembower, Teresa, additional, Wronkiewicz, Stephanie, additional, Rhodes, Nathaniel J, additional, Kling, Kendall, additional, and Sutton, Sarah, additional

Published
2023
Full Text
View/download PDF

5. 180. Impact of a two-step diagnostic bundle on hospital-onset Clostridioides difficile infection rates and treatment across a large health system.

Author

Polisetty, Radhika S, primary, Hoff, Brian M, additional, Moore, William J, additional, Postelnick, Michael, additional, Wang, Sheila K, additional, Zembower, Teresa, additional, Chao, Qi, additional, Malczynski, Michael, additional, Barajas, Grace, additional, Silkaitis, Christina, additional, Salim, Asra, additional, Borkowski, Jaime, additional, Shah, Rishita, additional, Quinn, Andrea, additional, Johnicker, Kyle, additional, Liang, Charlene, additional, Chang, Stephanie, additional, and Sutton, Sarah H, additional

Published
2022
Full Text
View/download PDF

8. Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam

Author

Alosaimy, Sara, primary, Lagnf, Abdalhamid M, additional, Hobbs, Athena L V, additional, Mubarez, Musa, additional, Kufel, Wesley D, additional, Morrisette, Taylor, additional, Polisetty, Radhika S, additional, Li, David, additional, Veve, Michael P, additional, Simon, Sam P, additional, Truong, James, additional, Finch, Natalie, additional, Venugopalan, Veena, additional, Rico, Matthew, additional, Amaya, Lee, additional, Yost, Christine, additional, Cubillos, Ashley, additional, Chandler, Elisabeth, additional, Patch, Megan, additional, Smith, Ian Murphy Kelsey, additional, Biagi, Mark, additional, Wrin, Justin, additional, Moore, W Justin, additional, Molina, Kyle C, additional, Rebold, Nicholas, additional, Holger, Dana, additional, Kunz Coyne, Ashlan J, additional, Jorgensen, Sarah C J, additional, Witucki, Paige, additional, Tran, Nikki N, additional, Davis, Susan L, additional, Sakoulas, George, additional, and Rybak, Michael J, additional

Published
2022
Full Text
View/download PDF

9. Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam.

Author

Alosaimy, Sara, Lagnf, Abdalhamid M, Hobbs, Athena L V, Mubarez, Musa, Kufel, Wesley D, Morrisette, Taylor, Polisetty, Radhika S, Li, David, Veve, Michael P, Simon, Sam P, Truong, James, Finch, Natalie, Venugopalan, Veena, Rico, Matthew, Amaya, Lee, Yost, Christine, Cubillos, Ashley, Chandler, Elisabeth, Patch, Megan, and Smith, Ian Murphy Kelsey

Subjects
NEPHROTOXICOLOGY, RESEARCH, CHRONIC kidney failure, BETA lactam antibiotics, CONFIDENCE intervals, SCIENTIFIC observation, MULTIVARIATE analysis, VANCOMYCIN, COMPARATIVE studies, RESEARCH funding, KAPLAN-Meier estimator, ODDS ratio, LOGISTIC regression analysis, PROPORTIONAL hazards models
Abstract

Background Vancomycin (VAN)-associated acute kidney injury (AKI) is increased when VAN is combined with certain beta-lactams (BLs) such as piperacillin-tazobactam (TZP) but has not been evaluated with ceftolozane-tazobactam (C/T). Our aim was to investigate the AKI incidence of VAN in combination with C/T (VAN/C/T) compared with VAN in combination to TZP (VAN-TZP). Methods We conducted a multicenter, observational, comparative study across the United States. The primary analysis was a composite outcome of AKI and risk, injury, failure, loss, end stage renal disease; Acute Kidney Injury Network; or VAN-induced nephrotoxicity according to the consensus guidelines. Multivariable logistic regression analysis was conducted to adjust for confounding variables and stratified Kaplan–Meir analysis to assess the time to nephrotoxicity between the 2 groups. Results We included VAN/C/T (n = 90) and VAN-TZP (n = 284) at an enrollment ratio of 3:1. The primary outcome occurred in 12.2% vs 25.0% in the VAN-C/T and VAN-TZP groups, respectively (P =.011). After adjusting for confounding variables, VAN-TZP was associated with increased odds of AKI compared with VAN-C/T; with an adjusted odds ratio of 3.308 (95% confidence interval, 1.560–6.993). Results of the stratified Kaplan–Meir analysis with log-rank time-to-nephrotoxicity analysis indicate that time to AKI was significantly shorter among patients who received VAN-TZP (P =.004). Cox proportional hazards analysis demonstrated that TZP was consistent with the primary analysis (P =.001). Conclusions Collectively, our results suggest that the AKI is not likely to be related to tazobactam but rather to piperacillin, which is a component in VAN-TZP but not in VAN-C/T. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States

Author

Rhodes, Nathaniel J, primary, Dairem, Atheer, additional, Moore, William J, additional, Shah, Anooj, additional, Postelnick, Michael J, additional, Badowski, Melissa E, additional, Michienzi, Sarah M, additional, Borkowski, Jaime L, additional, Polisetty, Radhika S, additional, Fong, Karen, additional, Spivak, Emily S, additional, Beardsley, James R, additional, Hale, Cory M, additional, Pallotta, Andrea M, additional, Srinivas, Pavithra, additional, and Schulz, Lucas T, additional

Published
2021
Full Text
View/download PDF

13. Multicenter point-prevalence evaluation of the utilization and safety of drug therapies for COVID-19

Author

Rhodes, Nathaniel J., primary, Dairem, Atheer, additional, Moore, William J., additional, Shah, Anooj, additional, Postelnick, Michael J., additional, Badowski, Melissa E., additional, Michienzi, Sarah M., additional, Borkowski, Jaime L., additional, Polisetty, Radhika S., additional, Fong, Karen, additional, Spivak, Emily S., additional, Beardsley, James R., additional, Hale, Cory M., additional, Pallotta, Andrea M., additional, Srinivas, Pavithra, additional, and Schulz, Lucas T., additional

Published
2020
Full Text
View/download PDF

16. A multi-center study of fidaxomicin use for Clostridium difficile infection

Author

Shah, Dhara N., primary, Chan, Fay S., additional, Kachru, Nandita, additional, Garcia, Krutina P., additional, Balcer, Holly E., additional, Dyer, April P., additional, Emanuel, John E., additional, Jordan, Michelle D., additional, Lusardi, Katherine T., additional, Naymick, Geri, additional, Polisetty, Radhika S., additional, Sieman, Lanny, additional, Tyler, Ashley M., additional, Johnson, Michael L., additional, and Garey, Kevin W., additional

Published
2016
Full Text
View/download PDF

19. Multicenter point-prevalence evaluation of the utilization and safety of drug therapies for COVID-19.

Author

Rhodes NJ, Dairem A, Moore W, Shah A, Postelnick MJ, Badowski ME, Michienzi SM, Borkowski JL, Polisetty RS, Fong K, Spivek ES, Beardsley JR, Hale CM, Pallotta AM, Srinivas P, and Schulz LT

Abstract

Background: There are currently no FDA-approved medications for the treatment of COVID-19. At the onset of the pandemic, off-label medication use was supported by limited or no clinical data. We sought to characterize experimental COVID-19 therapies and identify safety signals during this period., Methods: We conducted a non-interventional, multicenter, point prevalence study of patients hospitalized with suspected/confirmed COVID-19. Clinical and treatment characteristics within a 24-hour window were evaluated in a random sample of up to 30 patients per site. The primary objective was to describe COVID-19 targeted therapies. The secondary objective was to describe adverse drug reactions (ADRs)., Results: A total of 352 patients from 15 US hospitals were included. Most patients were treated at academic medical centers (53.4%) or community hospitals (42.6%). Sixty-seven patients (19%) were receiving drug therapy in addition to supportive care. Drug therapies included hydroxychloroquine (69%), remdesivir (10%), and interleukin-6 inhibitors (9%). Five patients (7.5%) were receiving combination therapy. Patients with a history of asthma (14.9% vs. 7%, p=0.037) and those enrolled in clinical trials (26.9% vs. 3.2%, p<0.001) were more likely to receive therapy. Among those receiving COVID-19 therapy, eight patients (12%) experienced an ADR, and ADRs were more commonly recognized in patients enrolled in clinical trials (62.5% vs 22%, OR=5.9, p=0.028)., Conclusions: While we observed high rates of supportive care for patients with COVID-19, we also found that ADRs were common among patients receiving drug therapy including in clinical trials. Comprehensive systems are needed to identify and mitigate ADRs associated with experimental COVID-19 therapies.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results